ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 479,25
0,23%
DAX
18 772,85
0,50%
Brent Oil
83,105
-1,01%
Bitcoin
61 034,01
-3,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. KALA BIO Inc (KALA)

  7. KALA BIO Inc (KALA) Actualités

KALA

KALA BIO (KALA)

KALA BIO Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KALA
DateHeureSourceTitreSymboleSociété
29/03/202413h00GlobeNewswire Inc.KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
04/03/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALAKALA BIO Inc
26/02/202414h00GlobeNewswire Inc.KALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceNASDAQ:KALAKALA BIO Inc
14/02/202419h09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KALAKALA BIO Inc
06/02/202414h00GlobeNewswire Inc.KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:KALAKALA BIO Inc
19/01/202422h01GlobeNewswire Inc.KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALAKALA BIO Inc
05/01/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALAKALA BIO Inc
13/11/202314h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALAKALA BIO Inc
13/11/202314h00GlobeNewswire Inc.KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
18/10/202322h04Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:KALAKALA BIO Inc
05/09/202314h00GlobeNewswire Inc.KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KALAKALA BIO Inc
04/08/202314h00GlobeNewswire Inc.KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
02/08/202322h01GlobeNewswire Inc.KALA BIO to Participate in Upcoming Investor Conferences in AugustNASDAQ:KALAKALA BIO Inc
02/08/202314h00GlobeNewswire Inc.Kala Pharmaceuticals Announces Name Change to KALA BIONASDAQ:KALAKALA BIO Inc
19/07/202322h01GlobeNewswire Inc.Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALAKALA BIO Inc
23/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KALAKALA BIO Inc
22/06/202322h48Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KALAKALA BIO Inc
15/06/202317h58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:KALAKALA BIO Inc
02/06/202314h00GlobeNewswire Inc.Kala Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:KALAKALA BIO Inc
31/05/202322h03Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:KALAKALA BIO Inc
11/05/202323h26Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KALAKALA BIO Inc
09/05/202314h00GlobeNewswire Inc.Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
28/04/202314h00GlobeNewswire Inc.Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCEDNASDAQ:KALAKALA BIO Inc
12/04/202314h00GlobeNewswire Inc.Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial DefectNASDAQ:KALAKALA BIO Inc
29/03/202314h00GlobeNewswire Inc.Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical AdvisorNASDAQ:KALAKALA BIO Inc
27/03/202314h00GlobeNewswire Inc.Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCEDNASDAQ:KALAKALA BIO Inc
15/03/202311h43Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:KALAKALA BIO Inc
08/03/202322h01GlobeNewswire Inc.Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:KALAKALA BIO Inc
03/03/202322h13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:KALAKALA BIO Inc
03/03/202314h17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:KALAKALA BIO Inc
 Showing the most relevant articles for your search:NASDAQ:KALA

Dernières Valeurs Consultées

EU
AI
Air Liquide
EU
CAP
Capgemini
NYSE
KO
Coca Cola
EU
GLE
Societe Generale
NASDAQ
AMZN
Amazon.com
EU
BEL20
Bel 20
EU
LR
Legrand
EU
ACA
Credit Agricole
EU
BN
Danone
EU
RI
Pernod Ricard
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
EU
EN
Bouygues
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés